These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 34367063)

  • 61. Type 2 diabetes mellitus: prevention of macrovascular complications.
    Meeuwisse-Pasterkamp SH; van der Klauw MM; Wolffenbuttel BH
    Expert Rev Cardiovasc Ther; 2008 Mar; 6(3):323-41. PubMed ID: 18327994
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cardiovascular Risk Factor Status in Hospitalized Patients With Type 2 Diabetes in China.
    Yang X; Liu Q; Fan Y; Ding L; Wang R; Hu G; Liu M
    Front Endocrinol (Lausanne); 2021; 12():664183. PubMed ID: 34367063
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Optimal glycaemic and blood pressure but not lipid targets are related to a lower prevalence of diabetic microvascular complications.
    Bashir M; Elhadd T; Dabbous Z; Gul W; Salameh O; Siddiqui M; Al-Muhannadi H; Petropoulos I; Khan A; Ponirakis G; Malik RA
    Diabetes Metab Syndr; 2021; 15(5):102241. PubMed ID: 34390975
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Racial disparities in cardiovascular risk factor control in an underinsured population with Type 2 diabetes.
    Wang Y; Katzmarzyk PT; Horswell R; Zhao W; Li W; Johnson J; Ryan DH; Hu G
    Diabet Med; 2014 Oct; 31(10):1230-6. PubMed ID: 24750373
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Prevalence of cardiovascular risk factors in non-menopausal and postmenopausal inpatients with type 2 diabetes mellitus in China.
    Zhou H; Zhang C; Ni J; Han X
    BMC Endocr Disord; 2019 Oct; 19(1):98. PubMed ID: 31601203
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effect of glycemic and lipid achievements on clinical outcomes type 2 diabetic, Chinese patients with stable coronary artery disease.
    Li S; Zhang Y; Guo YL; Zhu CG; Wu NQ; Qing P; Gao Y; Sun J; Liu G; Dong Q; Li JJ
    J Diabetes Complications; 2016; 30(1):115-20. PubMed ID: 26481154
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study.
    Li Y; Teng D; Shi X; Qin G; Qin Y; Quan H; Shi B; Sun H; Ba J; Chen B; Du J; He L; Lai X; Li Y; Chi H; Liao E; Liu C; Liu L; Tang X; Tong N; Wang G; Zhang JA; Wang Y; Xue Y; Yan L; Yang J; Yang L; Yao Y; Ye Z; Zhang Q; Zhang L; Zhu J; Zhu M; Ning G; Mu Y; Zhao J; Teng W; Shan Z
    BMJ; 2020 Apr; 369():m997. PubMed ID: 32345662
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effectiveness of sodium-glucose co-transporter-2 inhibitors on ischaemic heart disease.
    Shen Y; Zhou J; Shi L; Nauman E; Katzmarzyk PT; Price-Haywood EG; Horswell R; Chu S; Yang S; Bazzano AN; Nigam S; Hu G
    Diabetes Obes Metab; 2020 Jul; 22(7):1197-1206. PubMed ID: 32166884
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9
    Saeedi P; Petersohn I; Salpea P; Malanda B; Karuranga S; Unwin N; Colagiuri S; Guariguata L; Motala AA; Ogurtsova K; Shaw JE; Bright D; Williams R;
    Diabetes Res Clin Pract; 2019 Nov; 157():107843. PubMed ID: 31518657
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Standards of medical care for type 2 diabetes in China 2019.
    Jia W; Weng J; Zhu D; Ji L; Lu J; Zhou Z; Zou D; Guo L; Ji Q; Chen L; Chen L; Dou J; Guo X; Kuang H; Li L; Li Q; Li X; Liu J; Ran X; Shi L; Song G; Xiao X; Yang L; Zhao Z;
    Diabetes Metab Res Rev; 2019 Sep; 35(6):e3158. PubMed ID: 30908791
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program).
    Kosiborod M; Gomes MB; Nicolucci A; Pocock S; Rathmann W; Shestakova MV; Watada H; Shimomura I; Chen H; Cid-Ruzafa J; Fenici P; Hammar N; Surmont F; Tang F; Khunti K;
    Cardiovasc Diabetol; 2018 Nov; 17(1):150. PubMed ID: 30486889
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Impact of an intelligent chronic disease management system on patients with type 2 diabetes mellitus in a Beijing community.
    Xue-Juan W; Hao W; Cai-Ying G; Xin-Ying L; Hong-Yan J; Li W; Xiao-Ling G; Wan-Ying L; Wen-Juan G; Wan-Nian L
    BMC Health Serv Res; 2018 Oct; 18(1):821. PubMed ID: 30373577
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A seven-year study on an integrated hospital-community diabetes management program in Chinese patients with diabetes.
    Chen S; Hou X; Sun Y; Hu G; Zhou X; Xue H; Chen P; Wu J; Bao Y; Jia W
    Prim Care Diabetes; 2018 Jun; 12(3):231-237. PubMed ID: 29396207
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Achievement of guideline targets for blood pressure, lipid, and glycaemic control in type 2 diabetes: A meta-analysis.
    Khunti K; Ceriello A; Cos X; De Block C
    Diabetes Res Clin Pract; 2018 Mar; 137():137-148. PubMed ID: 29325774
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Prevalence of micro- and macrovascular diabetes complications at time of type 2 diabetes diagnosis and associated clinical characteristics: A cross-sectional baseline study of 6958 patients in the Danish DD2 cohort.
    Gedebjerg A; Almdal TP; Berencsi K; Rungby J; Nielsen JS; Witte DR; Friborg S; Brandslund I; Vaag A; Beck-Nielsen H; Sørensen HT; Thomsen RW
    J Diabetes Complications; 2018 Jan; 32(1):34-40. PubMed ID: 29107454
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Effect of Multifactorial Treatment Targets and Relative Importance of Hemoglobin A1c, Blood Pressure, and Low-Density Lipoprotein-Cholesterol on Cardiovascular Diseases in Chinese Primary Care Patients With Type 2 Diabetes Mellitus: A Population-Based Retrospective Cohort Study.
    Wan EYF; Fung CSC; Yu EYT; Chin WY; Fong DYT; Chan AKC; Lam CLK
    J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862945
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
    Neal B; Perkovic V; Mahaffey KW; de Zeeuw D; Fulcher G; Erondu N; Shaw W; Law G; Desai M; Matthews DR;
    N Engl J Med; 2017 Aug; 377(7):644-657. PubMed ID: 28605608
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Comparative effectiveness of glycemic control in patients with type 2 diabetes treated with GLP-1 receptor agonists: a network meta-analysis of placebo-controlled and active-comparator trials.
    Orme ME; Nguyen H; Lu JY; Thomas SA
    Diabetes Metab Syndr Obes; 2017; 10():111-122. PubMed ID: 28435304
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
    Marso SP; Daniels GH; Brown-Frandsen K; Kristensen P; Mann JF; Nauck MA; Nissen SE; Pocock S; Poulter NR; Ravn LS; Steinberg WM; Stockner M; Zinman B; Bergenstal RM; Buse JB; ;
    N Engl J Med; 2016 Jul; 375(4):311-22. PubMed ID: 27295427
    [TBL] [Abstract][Full Text] [Related]  

  • 80. 8. Cardiovascular Disease and Risk Management.
    American Diabetes Association
    Diabetes Care; 2016 Jan; 39 Suppl 1():S60-71. PubMed ID: 26696684
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.